Human scalp with dandruff, computer illustration. Roflumilast is a highly potent and selective phosphodiesterase type 4 inhibitor. Positive topline results were announced from a phase 3 trial ...

Please provide your email address to receive an email when new articles are posted on . A new drug application submitted to the FDA seeks approval of roflumilast foam 0.3% for adults and adolescents ...

It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes painful scalp conditions like seborrheic dermatitis, that can be easier said ...

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeks Once-daily ZORYVE foam 0.3% is approved ...

TORONTO, Oct. 21, 2024 /CNW/ - Arcutis Canada Inc., a commercial-stage company focused on delivering meaningful innovations in immuno-dermatology, is pleased to announce that Health Canada has ...

Please provide your email address to receive an email when new articles are posted on . Seborrheic dermatitis is often treated with topical antifungals or corticosteroids, which can be cumbersome on ...

The image shows severe seborrheic dermatitis. The next best step in treatment is to prescribe topical agents (Table) and refer the patient to a dermatologist. Seborrhea, which is thought to be caused ...

Hot off its first approval this summer in psoriasis, Arcutis Biotherapeutics’ roflumilast foam 0.3%, approved in cream form under the brand name Zoryve, is out to prove it’s no one-trick pony in itch.

(Reuters) -The U.S. Food and Drug Administration (FDA) on Friday approved Arcutis Biotherapeutics' drug for treating a skin condition called seborrheic dermatitis in individuals nine years of age and ...

This article was reviewed by Knox Beasley, MD. Flakes on your scalp making you feel self-conscious? Let’s talk about seborrheic dermatitis vs dandruff. Whether your scalp feels like a snowglobe thanks ...